INBX Inhibrx Biosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why INBX matters now
Inhibrx Biosciences, Inc. (INBX) is a US stock in Healthcare. The latest InvestLog snapshot shows $103.85 with +6.95% on the session and $1.52B in market capitalization; recent performance reads 1-month -15.03% and YTD +17.78%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-33.4M, and EPS of $-2.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.7%.
The latest indexable market news headline is "Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $325.00; recent insider activity includes MANHARD KIMBERLY filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-68.94
P/S
1050.12
EV/EBITDA
-10.33
DCF Value
$0.72
FCF Yield
-9.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-80.4%
Operating Margin
-9465.5%
Net Margin
-10014.2%
ROE
-563.9%
ROA
-70.8%
ROIC
-77.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-33.4M | $-2.15 |
| Q4 2025 | $0.00 | $-32.8M | $-2.11 |
| FY 2025 | $1.3M | $-140.1M | $-9.04 |
| Q3 2025 | $0.00 | $-35.3M | $-2.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$325.00
Target (Median)
$325.00
Target Range
$325.00 - $325.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.32
Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions. Its pipeline features several investigational therapies, notably INBRX-109. This tetravalent therapeutic candidate, which targets death-receptor 5, is undergoing Phase 2 clinical trials for managing conventional chondrosarcoma that is either unresectable or has spread. Another significant asset is INBRX-106, a hexavalent sdAb-based candidate engineered to engage OX4, also in Phase 2 clinical evaluation. This drug aims to treat a broad spectrum of advanced cancers, including metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA), renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was established in 2024 and is headquartered in La Jolla, California.